Results 121 to 130 of about 110,851 (248)

Small Molecule GSK-3 Inhibitors Safely Promote the Proliferation and Viability of Human Dental Pulp Stem Cells-In Vitro. [PDF]

Biomedicines, 2023
Hanna S, Aly R, Eldeen GN, Adanero Velasco A, Pérez Alfayate R.   +4 more
europepmc   +1 more source

Integrating Recycling and Emission Reduction: A Business Strategy Analysis With Multi‐Objective Mixed‐Integer Linear Programming Framework for Optimising Sustainable Closed‐Loop Supply Chain Network Design

Business Strategy and the Environment, EarlyView.
ABSTRACT This research develops an integrated mixed‐integer linear programming (MILP) model for closed‐loop supply chain network design that optimises competing economic and environmental objectives including profit maximisation, supplier quality improvement and CO2 emission reduction.
Reza Eslamipoor
wiley   +1 more source

Gsk-3-Mediated Proteasomal Degradation of ATF4 Is a Proapoptotic Mechanism in Mouse Pancreatic β-Cells. [PDF]

Int J Mol Sci, 2022
Nagao Y, Amo-Shiinoki K, Nakabayashi H, Hatanaka M, Kondo M, Matsunaga K, Emoto M, Okuya S, Tanizawa Y, Tanabe K.   +9 more
europepmc   +1 more source

Innovation in the Face of Necessity: A Mixed‐Method Study of Student's Experience From an Anatomy Education Program Focused on a Near‐Peer Tutoring Module

Clinical Anatomy, EarlyView.
ABSTRACT Following institutional changes that reduced access to cadaveric dissection, Paris‐Saclay University developed a two‐year elective anatomy pathway serving as a longitudinal progression toward near‐peer tutoring (NPT). Designed as a complement to the core curriculum, the program preserves engagement with human dissection while promoting ...
Maud Creze, Thomas Bessede, Florian Petit Lemaire, Olga Avilova, Fabrice Duparc, Sanjib Kumar Ghosh   +5 more
wiley   +1 more source

The budding yeast GSK-3 homologue Mck1 is an essential component of the spindle position checkpoint. [PDF]

Open Biol, 2022
Rathi S, Polat I, Pereira G.
europepmc   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

Arthritis &Rheumatology, Accepted Article.
Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +6 more
wiley   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology &Therapeutics, EarlyView.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Martin Weisser, Laura Blanco, Nicolas Frances, Eva Rossmann, Guido Steiner, Aintzane Zabaleta Azpiroz, Bruno Paiva, Ludovic Martinet, Tanja Fauti   +16 more
wiley   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

HemaSphere, 2023
Vania Hungria, Katja Weisel, Brooke Currie, Sue Perera, Neal Sule, Wei He, Astrid Mckeown, Sandhya Sapra, Linda Nelsen, Mary LI, Sophie Barale, Julia Boyle, Kaytlyn Mcpoyle, Meletios A. Dimopoulos   +13 more
doaj   +1 more source